Sei Investments Co. lifted its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 24.8% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 351,146 shares of the biotechnology company’s stock after acquiring an additional 69,673 shares during the period. Sei Investments Co.’s holdings in Ascendis Pharma A/S were worth $80,318,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently added to or reduced their stakes in the company. Advisory Services Network LLC acquired a new stake in Ascendis Pharma A/S in the third quarter worth about $26,000. Arax Advisory Partners grew its position in Ascendis Pharma A/S by 212.2% in the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 104 shares in the last quarter. Leonteq Securities AG acquired a new position in Ascendis Pharma A/S during the 4th quarter valued at about $36,000. Caitong International Asset Management Co. Ltd acquired a new position in Ascendis Pharma A/S during the 4th quarter valued at about $42,000. Finally, Global Retirement Partners LLC increased its stake in Ascendis Pharma A/S by 111.9% during the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 113 shares during the period.
Analyst Ratings Changes
ASND has been the topic of a number of recent analyst reports. Evercore restated an “outperform” rating and set a $329.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Wall Street Zen lowered shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Oppenheimer reiterated an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Tuesday, June 9th. Citigroup initiated coverage on Ascendis Pharma A/S in a report on Monday, May 18th. They set a “buy” rating and a $355.00 target price on the stock. Finally, Morgan Stanley upped their target price on Ascendis Pharma A/S from $256.00 to $275.00 and gave the stock an “overweight” rating in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Ascendis Pharma A/S has a consensus rating of “Buy” and a consensus price target of $296.72.
Ascendis Pharma A/S Price Performance
NASDAQ:ASND opened at $253.86 on Friday. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79. The business’s 50-day moving average price is $244.08 and its 200 day moving average price is $233.45. Ascendis Pharma A/S has a 52-week low of $160.86 and a 52-week high of $282.15. The firm has a market cap of $15.84 billion, a P/E ratio of 29.28 and a beta of 0.37.
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.11. The business had revenue of $285.45 million during the quarter, compared to analyst estimates of $362.47 million. As a group, sell-side analysts predict that Ascendis Pharma A/S will post 4.49 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, insider Flemming Steen Jensen sold 19,460 shares of Ascendis Pharma A/S stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jean Jacques Bienaime acquired 400 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were bought at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the acquisition, the director owned 400 shares in the company, valued at approximately $95,120. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 40.00% of the company’s stock.
Ascendis Pharma A/S Profile
Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.
The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.
Read More
- Five stocks we like better than Ascendis Pharma A/S
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND – Free Report).
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
